Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies

Schneeweiß, Andreas; Hartkopf, Andreas D.; Müller, Volkmar; Wöckel, Achim; Lux, Michael P.; Janni, Wolfgang; Ettl, Johannes; Belleville, Erik; Huober, Jens; Thill, Marc; Fasching, Peter A.; Kolberg, Hans‐Christian; Pöschke, Patrik; Welslau, Manfred; Overkamp, Friedrich; Tesch, Hans; Fehm, Tanja; Lüftner, Diana; Schütz, Florian

doi:10.1055/a-1111-2431

Cited by 17 publications

(17 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the improvement in the prognosis for patients with breast cancer and the increasing numbers of breast cancer survivors, 2 , 3 greater attention is being given to the physical and psychological side effects of systemic cancer therapy. During treatment and also after completing therapy, patients are particularly concerned with self-care, mind–body stabilization, and strategies for coping with cancer, and they wish to make their own contribution to recovery and want to participate actively in cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

“…The prognosis for patients with breast cancer has clearly improved over the last few years as a result of improving and targeted therapies. 2 , 3 With the increasing numbers of breast cancer survivors and longer lifespans, attention is now turning to the physical and psychological side effects, the patients’ quality of life, and ways of coping with the cancer. Cancer treatments are often associated with side effects, a reduction in the quality of life, and psychological symptoms, creating an additional burden for patients.…”

Section: Introductionmentioning

confidence: 99%

“…1 The prognosis for patients with breast cancer has clearly improved over the last few years as a result of improving and targeted therapies. 2,3 With the increasing numbers of 990108I CTXXX10.1177/1534735421990108Integrative Cancer TherapiesTheuser et al research-article20212021 1 Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany 2 Hospital Bayreuth GmbH, Bayreuth, Germany breast cancer survivors and longer lifespans, attention is now turning to the physical and psychological side effects, the patients' quality of life, and ways of coping with the cancer. Cancer treatments are often associated with side effects, a reduction in the quality of life, and psychological symptoms, creating an additional burden for patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Active Participation, Mind–Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

Purpose: Increasing numbers of breast cancer survivors have led to a growing demand for integrative medicine. When patients have completed treatments associated with severe side effects, attention turns to reducing psychological symptoms, coping behavior, and self-care. The aim of this study was to assess patient-reported benefits in relation to active participation, mind–body stabilization, and coping strategies in breast cancer patients receiving integrative medicine. Methods: In a cross-sectional study, health counseling and treatment provided by a standardized integrative medicine consultancy service at the University Breast Center of Franconia were evaluated in 75 breast cancer patients over a 15-month period. At the baseline, the patients answered a questionnaire on their medical history, symptoms, and the treatment goals they were hoping to achieve with integrative medicine. Patient-reported outcomes relative to active participation, mind–body stabilization, and coping strategies were analyzed. Results: A large majority of the patients had previous experience with integrative medicine (91%). Most reported that they achieved their treatment goals with integrative medicine. Ninety-one percent achieved active participation in cancer treatment, 90% mind–body stabilization, and 79% improvement in coping strategies. Besides active participation, which was greatest in patients with stable disease, the success of integrative therapy was independent of age, concomitant diseases, previous integrative medicine experience, treatment state, and systemic cancer therapy. Conclusion: Breast cancer patients benefit from the counseling and treatment provided with integrative medicine in mind–body stabilization and coping with cancer. Active participation in cancer treatment is important for the patients. Integrative treatment services should form part of routine patient care.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Active Participation, Mind–Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Die Versorgung von Patientinnen mit einem Mammakarzinom ist komplex und umfasst die Prävention, Früherkennung, Behandlung und Nachsorge. In jedem dieser Bereiche sind in den letzten Jahren deutliche Fortschritte erzielt worden 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 .…”

Section: Einführungunclassified

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Lux

Schneeweiß

Hartkopf

et al. 2021

Geburtshilfe Frauenheilkd

Self Cite

View full text Add to dashboard Cite

In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatment with pertuzumab, T-DM1, neratinib and, soon, also tucatinib and trastuzumab deruxtecan (neither of which has yet been authorised in Europe). In patients with HER2−/HR+ breast cancer, CDK4/6 inhibitors and the PIK3CA inhibitor alpelisib are of particular importance. Further novel therapies, such as Akt kinase inhibitors and oral SERDs (selective estrogen receptor down regulators), are already being investigated in ongoing clinical trials. These therapeutic agents are not only being introduced into curative, (neo-)adjuvant therapeutic settings for HER2-positive tumours; a first favourable study on abemaciclib as an adjuvant therapy has now also been published. In patients with triple-negative breast cancer, after many years of negative study results with the Trop-2 antibody drug conjugate (ADC) sacituzumab govitecan, a randomised study has been published that may represent a significant therapeutic advance. This review describes the latest developments in breast cancer subsequent to the ESMO Congress 2020.

show abstract

“…The biomarker profile, especially hormone receptor status and (HER2) status, of primary breast cancers and breast cancer recurrences is essential for treatment decision-making [ 2 , 9 , 10 , 11 , 12 , 13 ]. It is known that a change in biomarker profile can occur from primary breast cancer to breast cancer recurrences or metastases [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Discordance between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence as a Function of Distance

Jud

Hatko²,

Emons

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Risk factors for ipsilateral breast cancer tumor recurrence (IBTR) are well established and include grading, nodal status, and receptor status. Little is known about the influence of the local distance between the primary tumor and recurrences on changes in tumor characteristics and prognosis. Methods: In a retrospective setting, we analyzed primary breast cancers and their recurrences. Localizations of primary and recurrent breast cancer were recorded to calculate the relative distance in pixels. Analysis was performed regarding tumor characteristics, relative distance between both, and their impact on breast cancer prognosis. Results: In a cohort of 142 patients with ipsilateral recurrence, no statistically significant difference could be shown in the change in tumor characteristics depending on distance. Progesterone receptor (PR) and estrogene receptor (ER) status changed in 22.7% and 14.9% of cases, respectively. human epidermal growth factor receptor 2 (ERBB2, HER2) status changed in 18.3% of cases. Survival was in accordance with the literature, with luminal-A-like tumors as best and triple negative breast cancers (TNBC) as worst prognosis. With a threshold of 162 pixels, the survival was significantly better in the group with shorter distance. Conclusion: Change in tumor characteristics from primary breast cancer to recurrence occurs more often in PR than ER. In contrast to other work, in this dataset, recurrences with a larger distance to the primary tumor had a worse prognosis in univariate analysis. A Cox model might indicate the possibility that this influence is independent of other risk factors.

show abstract

Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies

Cited by 17 publications

References 78 publications

Active Participation, Mind–Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients

Active Participation, Mind–Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Discordance between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence as a Function of Distance

Contact Info

Product

Resources

About